Ingrid A.M. Mandjes

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Leonie Voorwerk, Maarten Slagter, Hugo M. Horlings et al. · Nature Medicine · 2019 · 889 citations · Full text

Medicine, Immunology, Oncology +17

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven et al. · The Lancet Oncology · 2018 · 445 citations · Full text

Medicine, Oncology, Breast Oncology +15

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

Jetske M. Meerum Terwogt, W.W. ten Bokkel Huinink, Jan H.M. Schellens et al. · Anti-Cancer Drugs · 2001 · 278 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +17

Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual<i>ERBB2</i>Blockade in Patients With<i>ERBB2</i>-Positive Breast Cancer

Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven et al. · JAMA Oncology · 2021 · 144 citations · Full text

Medicine, Oncology, Breast Oncology +15

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response

Esther H. Lips, Lennart Mulder, Jorma J. de Ronde et al. · Breast Cancer Research and Treatment · 2013 · 116 citations · Full text

Medicine, Oncology, Breast Oncology +13